Soligenix announces scheduling of type a meeting with the u.s. fda to review proposed study design for a second phase 3 study evaluating hybryte™ in the treatment of cutaneous t-cell lymphoma

Update on fda meeting outcome expected next month princeton, n.j. , may 11, 2023 /prnewswire/ -- soligenix, inc. (nasdaq: sngx) (soligenix or the company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the united states (u.s.) food and drug administration (fda) has granted a type a meeting to discuss the design of a second, phase 3 pivotal study evaluating hybryte™ (hypericin sodium) in the treatment of early stage cutaneous t-cell lymphoma (ctcl), a rare cancer, where it has successfully demonstrated statistically significant results in the first phase 3 clinical trial.
SNGX Ratings Summary
SNGX Quant Ranking